WO2001080897A3 - Compositions and methods for in vivo delivery of polynucleotide-based therapeutics - Google Patents

Compositions and methods for in vivo delivery of polynucleotide-based therapeutics Download PDF

Info

Publication number
WO2001080897A3
WO2001080897A3 PCT/US2001/012975 US0112975W WO0180897A3 WO 2001080897 A3 WO2001080897 A3 WO 2001080897A3 US 0112975 W US0112975 W US 0112975W WO 0180897 A3 WO0180897 A3 WO 0180897A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
polynucleotide
compositions
vivo delivery
based therapeutics
Prior art date
Application number
PCT/US2001/012975
Other languages
French (fr)
Other versions
WO2001080897A2 (en
Inventor
Jukka Hartikka
Loretta Sukhu
Original Assignee
Jukka Hartikka
Loretta Sukhu
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jukka Hartikka, Loretta Sukhu, Vical Inc filed Critical Jukka Hartikka
Priority to EP01928741A priority Critical patent/EP1278551A2/en
Priority to CA002407074A priority patent/CA2407074A1/en
Publication of WO2001080897A2 publication Critical patent/WO2001080897A2/en
Publication of WO2001080897A3 publication Critical patent/WO2001080897A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to pharmaceutical compositions and methods to improve expression of exogenous polypeptides into vertebrate cells in vivo, utilizing delivery of polynucleotides encoding such polypeptides. More particularly, the present invention provides the use of salts, in particular sodium and potassium salts of phosphate, in aqueous solution, and auxiliary agents, in particular detergents and surfactants, in pharmaceutical compositions and methods useful for direct polynucleotide-based polypeptide delivery into the cells of vertebrates.
PCT/US2001/012975 2000-04-21 2001-04-23 Compositions and methods for in vivo delivery of polynucleotide-based therapeutics WO2001080897A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01928741A EP1278551A2 (en) 2000-04-21 2001-04-23 Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
CA002407074A CA2407074A1 (en) 2000-04-21 2001-04-23 Compositions and methods for in vivo delivery of polynucleotide-based therapeutics

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19882300P 2000-04-21 2000-04-21
US60/198,823 2000-04-21
US25315300P 2000-11-28 2000-11-28
US60/253,153 2000-11-28

Publications (2)

Publication Number Publication Date
WO2001080897A2 WO2001080897A2 (en) 2001-11-01
WO2001080897A3 true WO2001080897A3 (en) 2002-04-25

Family

ID=26894181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012975 WO2001080897A2 (en) 2000-04-21 2001-04-23 Compositions and methods for in vivo delivery of polynucleotide-based therapeutics

Country Status (4)

Country Link
US (1) US6875748B2 (en)
EP (1) EP1278551A2 (en)
CA (1) CA2407074A1 (en)
WO (1) WO2001080897A2 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105574B1 (en) 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
EP1032428B1 (en) * 1997-11-20 2003-06-18 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
JP4800485B2 (en) * 1999-03-26 2011-10-26 バイカル インコーポレイテッド Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
BR0108959A (en) * 2000-03-03 2003-10-14 Valentis Inc Improved poloxamer or poloxamine compositions for nucleic acid delivery
US7256180B2 (en) * 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
US20020042388A1 (en) 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
BR0115392A (en) * 2000-11-03 2004-06-15 Biomedicines Inc Method for the treatment of an interferon-sensitive disease in a warm-blooded animal, method for individualizing the dosages of an interferon in treatment, method for manufacturing a long-term therapeutic effect delivery device of a drug over a period of time, and useful set for delivering a relatively constant amount of a drug
EP1232758A1 (en) * 2001-02-19 2002-08-21 Aventis Pasteur Polynucleotide formulated for improved intracellular transfer
US20030091544A1 (en) * 2001-03-13 2003-05-15 Vical Incorporated Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
EP1536839B1 (en) * 2001-11-09 2010-09-15 Intarcia Therapeutics, Inc Combination therapy comprising omega-interferon for treating infection with hepatitis c virus or yellow fever virus
EP1453536A4 (en) * 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd Composition for the preservation of viruses
US20050232899A1 (en) * 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US6830744B2 (en) * 2002-05-31 2004-12-14 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
EP1575505A4 (en) * 2002-09-10 2007-01-24 Vical Inc Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
EP1545432A4 (en) * 2002-09-26 2007-03-14 Pfizer Prod Inc Use of excipients to increase dna uptake by swine muscle cells
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1578193A4 (en) * 2002-12-23 2011-06-15 Vical Inc Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
ATE471335T1 (en) 2002-12-23 2010-07-15 Vical Inc VACCINES AGAINST INFECTIONS WITH THE HUMAN CYTOMEGALIVIRUS BASED ON CODONE-OPTIMIZED POLYNUCLEOTIDES
EP1581201A4 (en) * 2002-12-23 2011-03-30 Vical Inc Method for producing sterile polynucleotide based medicaments
US7682626B2 (en) * 2003-02-07 2010-03-23 Roche Madison Inc. Polyvinylethers for delivery of polynucleotides to mammalian cells
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
GB0401513D0 (en) * 2004-01-23 2004-02-25 Camurus Ab Compositions
EP1766094A4 (en) 2004-05-18 2009-11-25 Vical Inc Influenza virus vaccine composition and method of use
US7422875B2 (en) 2004-07-20 2008-09-09 Board Of Regents Of The University Of Nebraska Compositions and methods for increasing protein production
US20060134221A1 (en) * 2004-12-03 2006-06-22 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20060216315A1 (en) * 2005-03-16 2006-09-28 Yoo Tai J Cockroach allergen gene expression and delivery systems and uses
US20100226932A1 (en) * 2006-02-22 2010-09-09 Novavax, Inc. Adjuvant and Vaccine Compositions
US7820443B2 (en) * 2006-03-08 2010-10-26 Yeastern Biotech Co., Ltd. Fast method of transforming competent cells
MX2008014870A (en) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator.
US8227437B2 (en) * 2006-06-22 2012-07-24 Tai June Yoo Restoration of hearing loss
ES2422864T3 (en) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Osmotic release systems and piston units
JP5829377B2 (en) * 2007-02-06 2015-12-09 ジュン ヨー，タイ Treatment and prevention of neurodegenerative diseases using gene therapy
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
CA2684923C (en) 2007-05-02 2015-01-06 Merial Limited Dna plasmids having improved expression and stability
WO2008137881A2 (en) 2007-05-04 2008-11-13 The Ohio State University Research Foundation Ehrlichia ewingii proteins, nucleic acids, and methods of their use
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
WO2011037623A1 (en) 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US8815229B2 (en) 2009-10-12 2014-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Granulysin in immunotherapy
US9572895B2 (en) 2010-08-06 2017-02-21 The Board Of Trustees Of The University Of Illinois Multiplexed supramolecular assemblies for non-viral delivery of genetic material
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012135701A2 (en) 2011-03-31 2012-10-04 The Ohio State University Compositions and methods for the detection of anaplasma platys
CA2839896A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
EP2925352B1 (en) 2012-12-03 2019-10-02 Ohio State Innovation Foundation Ehrlichial invasin for immunization, diagnosis, and cell delivery
EP3369435B1 (en) 2013-07-18 2019-09-04 Xalud Therapeutics, Inc. Composition for the treatment of inflammatory joint disease
US10872313B2 (en) 2015-06-02 2020-12-22 ROCA Medical Ltd. Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10548974B2 (en) 2015-06-02 2020-02-04 ROCA Medical Ltd. Therapeutic treatment kit for allergies based on DNA profiles
US10369215B2 (en) * 2015-06-02 2019-08-06 ROCA Medical Ltd. Predilution sets for distributing antigens
CN113598842A (en) 2015-06-03 2021-11-05 因塔西亚制药公司 Implant placement and removal system
WO2017031353A1 (en) 2015-08-19 2017-02-23 Rutgers, The State University Of New Jersey Novel methods of generating antibodies
AU2016367712B2 (en) 2015-12-09 2021-10-07 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
US10441209B2 (en) * 2016-02-04 2019-10-15 ROCA Medical Ltd. Antigen regional testing kit
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
AU2018214451B2 (en) 2017-02-06 2022-02-03 Meat & Livestock Australia Limited Immunostimulating compositions and uses therefore
AU2018254776B2 (en) 2017-04-22 2022-06-30 Immunomic Therapeutics, Inc. Improved LAMP constructs
US20200087365A1 (en) 2017-05-02 2020-03-19 Immunomic Therapeutics, Inc Improved lamp constructs comprising cancer antigens
US20210205382A1 (en) * 2018-05-17 2021-07-08 University of Florida Research Foundation, Incorporation Methods and compositions for using metal elements in aav gene therapy
AU2020365133A1 (en) * 2019-10-16 2022-04-28 Orchard Therapeutics (Europe) Limited Compositions and methods for modifying eukaryotic cells
US20240108703A1 (en) 2019-10-18 2024-04-04 Immunomic Therapeutics, Inc. Improved LAMP Constructs Comprising Cancer Antigens
CN110791502B (en) * 2019-12-04 2022-07-08 陕西理工大学 Human RBP4 promoter fragment and application thereof
WO2022051549A1 (en) 2020-09-04 2022-03-10 Rutgers, The State University Of New Jersey Sars-cov-2 vaccines and antibodies
KR20230127977A (en) * 2020-10-02 2023-09-01 이뮨온, 인코포레이티드 Polynucleotide Vaccines and Methods of Use Thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021470A2 (en) * 1995-01-13 1996-07-18 Genemedicine, Inc. Compositions of nucleic acid and viscosity-increasing polymers for use in gene therapy
WO1997030731A2 (en) * 1996-02-21 1997-08-28 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
CA2284399A1 (en) * 1998-09-30 2000-03-30 Serge Braun Use of magnesium (mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US6706694B1 (en) * 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US20030186913A1 (en) 1990-03-21 2003-10-02 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5622649A (en) 1991-06-27 1997-04-22 Emory University Multiple emulsions and methods of preparation
US5470568A (en) 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
ATE301201T1 (en) 1993-06-07 2005-08-15 Vical Inc PLASMIDS USABLE FOR GENE THERAPY
AU8076494A (en) 1993-10-15 1995-05-04 Cytrx Corporation Therapeutic delivery compositions and methods of use thereof
WO1995025504A1 (en) 1994-03-18 1995-09-28 Pharmavene, Inc. Emulsified drug delivery systems
EP1181937A3 (en) 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US5656611A (en) 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US5641665A (en) 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5883103A (en) 1995-06-07 1999-03-16 Shire Laboratories Inc. Oral acyclovir delivery
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
WO1997019675A2 (en) 1995-11-30 1997-06-05 Vical Incorporated Complex cationic lipids
US5994317A (en) 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5861397A (en) * 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
EP1032428B1 (en) 1997-11-20 2003-06-18 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
WO1999031262A2 (en) 1997-12-16 1999-06-24 Valentis, Inc. Needle-free injection of formulated nucleic acid molecules
AU4219399A (en) 1998-06-08 1999-12-30 Valentis, Inc. Formulations for electroporation
WO2000040273A2 (en) 1999-01-08 2000-07-13 Vical Incorporated Treatment of viral diseases using an interferon omega expressing polynucleotide
JP4800485B2 (en) 1999-03-26 2011-10-26 バイカル インコーポレイテッド Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
WO2001009303A2 (en) 1999-07-30 2001-02-08 Vical Inc. Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER
BR0108959A (en) 2000-03-03 2003-10-14 Valentis Inc Improved poloxamer or poloxamine compositions for nucleic acid delivery
EP1283727A4 (en) 2000-04-28 2007-10-10 Supratek Pharma Inc Compositions and methods for inducing activation of dendritic cells
CA2406013A1 (en) 2000-05-12 2001-11-22 Supratek Pharma Inc. Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers
AU2001270147A1 (en) 2000-06-23 2002-01-08 Merck & Co., Inc. Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use
EP1578193A4 (en) 2002-12-23 2011-06-15 Vical Inc Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021470A2 (en) * 1995-01-13 1996-07-18 Genemedicine, Inc. Compositions of nucleic acid and viscosity-increasing polymers for use in gene therapy
WO1997030731A2 (en) * 1996-02-21 1997-08-28 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
CA2284399A1 (en) * 1998-09-30 2000-03-30 Serge Braun Use of magnesium (mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DANKO ISTVAN ET AL: "Pharmacological enhancement of in vivo foreign gene expression in muscle.", GENE THERAPY, vol. 1, no. 2, 1994, pages 114 - 121, XP001030901 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; January 2000 (2000-01-01), NGUYEN H -K ET AL: "Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents.", XP002182535, Database accession no. PREV200000129198 *
DAVIS H L ET AL: "DIRECT GENE TRANSFER INTO SKELETAL MUSCLE IN VIVO: FACTORS AFFECTING EFFICIENCY OF TRANSFER AND STABILITY OF EXPRESSION", HUMAN GENE THERAPY, XX, XX, vol. 4, 1993, pages 151 - 159, XP000995687, ISSN: 1043-0342 *
GENE THERAPY., vol. 7, no. 2, January 2000 (2000-01-01), pages 126 - 138, ISSN: 0969-7128 *
HARTIKKA J ET AL: "AN IMPROVED PLASMID DNA EXPRESSON VECTOR FOR DIRECT INJECTION INTO SKELETAL MUSCLE", HUMAN GENE THERAPY, XX, XX, vol. 7, no. 10, 20 June 1996 (1996-06-20), pages 1205 - 1217, XP001030903, ISSN: 1043-0342 *
HARTIKKA J ET AL: "Sodium phosphate enhances plasmid DNA expression in vivo.", GENE THERAPY, vol. 7, no. 14, July 2000 (2000-07-01), pages 1171 - 1182, XP001030904, ISSN: 0969-7128 *
KARIKO K ET AL: "PHOSPHATE-ENHANCED TRANSFECTION OF CATIONIC LIPID-COMPLEXED MRNA AND PLASMID DNA", BIOCHIMICA ET BIOPHYSICA ACTA, AMSTERDAM, NL, vol. 1369, no. 2, 1998, pages 320 - 334, XP001030876, ISSN: 0006-3002 *
KICHLER A ET AL: "Influence of the DNA complexation medium on the transfection efficiency of lipospermine/DNA particles.", GENE THERAPY, vol. 5, no. 6, June 1998 (1998-06-01), pages 855 - 860, XP001030902, ISSN: 0969-7128 *

Also Published As

Publication number Publication date
US6875748B2 (en) 2005-04-05
US20020019358A1 (en) 2002-02-14
WO2001080897A2 (en) 2001-11-01
EP1278551A2 (en) 2003-01-29
CA2407074A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
WO2001080897A3 (en) Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
MX2009002547A (en) Fusion peptide therapeutic compositions.
TNSN04249A1 (en) Acidic insulin preparations with improved stability
IL172835A0 (en) A composition for stabilizing active protein ingredients in pharmaceutical composition containing at least 2 amino acids
TR200201874T2 (en) New compounds and compositions as protease inhibitors.
AU2001291621A1 (en) Free-flowing, amphiphilic, non-ionic oligoesters
IL155806A0 (en) Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
GB2360786B (en) Hard surface cleaning composition
WO2002016583A3 (en) Constructs and their use in metabolic pathway engineering
WO2006023591A8 (en) Enhanced oil delivery from structured surfactant formulations
FR2811552B1 (en) COMPOSITION, IN PARTICULAR COSMETIC OR PHARMACEUTICAL, IN SOLID FORM
IL168836A (en) Pyrimidine-sulfamides and their use as endothelin receptor antagonist
NZ593190A (en) Factor viii formulations
WO2012045907A4 (en) Detergent compositions
RS53550B1 (en) Adjuvant compositions comprising a non-ionic isotonicity agent
PL348048A1 (en) Liquid cleaning agent or detergent composition
MX2007002874A (en) Improvements in or relating to organic compositions.
SI1407763T1 (en) Compositions containing a cosmetically active organic acid and a legume product
HK1038179A1 (en) New oral formulation for 5-ht4 agonists or antagonists
PL1868631T3 (en) Use of compounds inducing the synthesis of sirt proteins in or for the preparation of a cosmetic or pharmaceutical composition
PL321708A1 (en) Pasty cleaning agent
MXPA05009135A (en) Liquid formulations of tumor necrosis factor-binding proteins.
MXPA04003540A (en) Use of a copolymer to produce a galenic form containing a peptide or a protein as active agent.
MXPA03000430A (en) Novel arylethene-sulfonamides.
PE20010596A1 (en) CHEMOTRIPSIN FREE TRYPSIN

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2407074

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001928741

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001928741

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001928741

Country of ref document: EP